Business Context and Reporting Period
This Form 8-K is a current report filed by IDEAYA Biosciences, Inc. on October 24, 2023. The filing provides preliminary financial estimates for the quarter ended September 30, 2023, and details recent equity financing activities under an "at-the-market" (ATM) program.
Key Financial Metrics
- Cash and Liquidity: As of September 30, 2023, the Company estimates approximately $511.1 million in cash, cash equivalents, and marketable securities.
- Revenue and Profit: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
- Debt: The filing text does not provide specific values for outstanding debt.
- Equity Financing: Between July 1, 2023, and October 20, 2023, the Company sold 1,036,421 shares of common stock under its ATM facility at a weighted average price of approximately $26.27 per share.
Material Changes and ATM Program Status
The Company entered into an ATM facility with Jefferies LLC in June 2023, authorizing the sale of up to $250.0 million of common stock. As of October 20, 2023, approximately $222.5 million of common stock remains available to be sold under this facility. The preliminary cash balance of $511.1 million is subject to change upon completion of the quarter-end financial close.
Guidance, Outlook, and Risks
- Preliminary Nature of Data: The financial data presented is unaudited, preliminary, and based on estimates. The Company has not completed its financial close for the quarter ended September 30, 2023.
- Accounting Review: PricewaterhouseCoopers LLP has not audited or reviewed the preliminary data and expresses no assurance regarding it.
- Future Adjustments: The reported cash balance could change as the review of financial statements continues.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and marketable securities balance in the upcoming Form 10-Q for the quarter ended September 30, 2023.
- Confirm the total proceeds generated from the ATM sales between July 1 and October 20, 2023, against the share count and weighted average price provided.
- Monitor subsequent filings for updates on the remaining $222.5 million capacity under the ATM facility.
- Review the full Form 10-Q for revenue, operating expenses, and net loss figures which are not included in this 8-K.